Conexeu Sciences Inc. sold unregistered shares; disclosed a material event
SEC 8-KRead source ↗
Conexeu Sciences Inc. is a US-listed company in the health care equipment industry. Its financial year ends in October.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders2 buying, 0 selling4 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
- Funds8 adding, 0 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 190% in the quarter to 2026-07-31.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Latest results
- Earnings per share
- -$0.29 against an average estimate of -$0.10: missed by 190.0%
Price chart
- 1 day-5.5%
- 1 week-18.4%
- 1 month-22.6%
Loading chart…
Third-party market data · may be delayed
At a glance
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Share issue
- Share issue
Conexeu Sciences Inc. sold unregistered shares
SEC 8-KRead source ↗ - Share issue
Conexeu Sciences Inc. sold unregistered shares
SEC 8-KRead source ↗ - Announcement
Conexeu Sciences Inc. made a public disclosure
SEC 8-KRead source ↗
No model value for Conexeu Sciences Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Conexeu Sciences Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.5%: the 10-year Treasury yield (4.9%) plus a beta of 1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Conexeu Sciences Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.
Forecasts and guidance
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.40 | −29% | — | — |
| Next | −$0.53 | −33% | — | 0% |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | −$0.10 | −$0.29 | −190.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- — of tradable shares
- Days to cover
- 1.04 at average volume
- Short interest, 1 month
- +73% to October 15, 2026
- Held by institutions
- 8% of shares
- Held by insiders
- 47.6% of shares
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- −44.0%
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $282,501
- Institutions reporting
- 8
- Positions opened / closed
- 8 / 0
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| UBS Group AG | $133,923 | 12K | 47.4% | — |
| Morgan Stanley | $64,111 | 6K | 22.7% | — |
| Citigroup Inc | $56,991 | 5K | 20.2% | — |
| Hollencrest Capital Management | $10,920 | 1K | 3.9% | — |
| Royal Bank Of Canada | $10,000 | 1K | 3.5% | — |
| Integrated Wealth Concepts LLC | $4,368 | 0K | 1.5% | — |
| Jones Financial Companies LLLP | $1,096 | 0K | 0.4% | — |
| Osaic Holdings, Inc. | $1,092 | 0K | 0.4% | — |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Conexeu Sciences Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $1.3M 4 trades by 2 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $1.3M net buying
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Purcell Lynn Sebastian Director | October 15, 2026 | Buy | 166,666 | $3.00 | $499,998 |
| Purcell Lynn Sebastian Director | June 18, 2026 | Buy | 202,500 | $0.80 | $162,000 |
| Purcell Lynn Sebastian Director | May 12, 2026 | Buy | 422,500 | $0.80 | $338,000 |
| Onepointtwo Capital Ventures Llc 10% owner | May 12, 2026 | Buy | 422,500 | $0.80 | $338,000 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Recent SEC filings
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Conexeu Sciences Inc. in brief
- What does Conexeu Sciences Inc. do?
- Conexeu Sciences Inc. is a US-listed company in the health care equipment industry. Its financial year ends in October.
- What is Conexeu Sciences Inc.'s stock ticker?
- Conexeu Sciences Inc. trades under the ticker CNXU on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Conexeu Sciences Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are UBS Group AG, Morgan Stanley and Citigroup Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Conexeu Sciences Inc. stock?
- Over the last 12 months, Conexeu Sciences Inc.'s directors and officers reported 4 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
Follow research on Conexeu Sciences Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.